PT  - JOURNAL ARTICLE
AU  - Karaba, Andrew H.
AU  - Kim, Jake D.
AU  - Chiang, Teresa P-Y
AU  - Alejo, Jennifer L.
AU  - Abedon, Aura T.
AU  - Mitchell, Jonathan
AU  - Chang, Amy
AU  - Eby, Yolanda
AU  - Johnston, Trevor Scott
AU  - Aytenfisu, Tihitina
AU  - Hussey, Casey
AU  - Jefferis, Alexa
AU  - Fortune, Nicole
AU  - Abedon, Rivka
AU  - Thomas, Letitia
AU  - Warren, Daniel S.
AU  - Sitaras, Ioannis
AU  - Pekosz, Andrew
AU  - Avery, Robin K.
AU  - Massie, Allan B.
AU  - Clarke, William A.
AU  - Tobian, Aaron A.R.
AU  - Segev, Dorry L.
AU  - Werbel, William A.
TI  - Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients
AID  - 10.1101/2022.05.24.22275467
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.24.22275467
4099  - http://medrxiv.org/content/early/2022/05/26/2022.05.24.22275467.short
4100  - http://medrxiv.org/content/early/2022/05/26/2022.05.24.22275467.full
AB  - Neutralizing antibody responses are attenuated in many solid organ transplant recipients (SOTRs) despite SARS-CoV-2 vaccination. Pre-exposure prophylaxis (PrEP) with the monoclonal antibody combination Tixagevimab and Cilgavimab (T+C) might augment immunoprotection, yet activity against Omicron sublineages in vaccinated SOTRs is unknown. Vaccinated SOTRs who received 300+300mg T+C (either single dose or two 150+150mg doses) within a prospective observational cohort submitted pre- and post-injection samples between 1/10/2022-4/4/2022. Binding antibody (anti-receptor binding domain [RBD], Roche) and surrogate neutralization (%ACE2 inhibition; ≥20% connoting neutralizing inhibition, Meso Scale Discovery) were measured against variants including Omicron sublineages BA.1 and BA.2. Data were analyzed using the Wilcoxon matched-pairs signed-rank test and McNemar’s test. Among 61 participants, median (IQR) anti-RBD increased from 424 (IQR <0.8-2322.5) to 3394.5 (IQR 1403.9-7002.5) U/ml post T+C (p<0.001). The proportion demonstrating vaccine strain neutralizing inhibition increased from 46% to 100% post-T+C (p<0.001). BA.1 neutralization was low and did not increase (8% to 16% of participants post-T+C, p=0.06). In contrast, BA.2 neutralization increased from 7% to 72% of participants post-T+C (p<0.001). T+C increased anti-RBD levels, yet BA.1 neutralizing activity was minimal. Encouragingly, BA.2 neutralization was augmented and in the current variant climate T+C PrEP may serve as a useful complement to vaccination in high-risk SOTRs.Competing Interest StatementDr Segev reports receiving consulting and/or speaking honoraria from Sanofi, Novartis, Veloxis, Mallinckrodt, Jazz Pharmaceuticals, CSL Behring, Thermo Fisher Scientific, Caredx, Transmedics, Kamada, MediGO, Regeneron, AstraZeneca, Takeda/Shire, and Bridge to Life. Dr. Avery has grant/research support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, Regeneron, and Takeda/Shire. Dr. Karaba has received consulting fees from Roche.Funding StatementThis work was supported by the Ben-Dov family, the Trokhan Patterson family, The ASTS Fryer Resident Scientist Award (Dr. Mitchell), grants 5T32DK007713 (Dr. Alejo), T32DK007732 (Dr. Chang), and K01DK101677 (Dr. Massie) from the National Institute of Diabetes and Digestive and Kidney Diseases; grant K24AI144954 (Dr. Segev), K08AI156021 (Dr. Karaba), U01AI138897, 3U01AI138897-04S1, and K23AI157893 (Dr. Werbel) from the National Institute of Allergy and Infectious Diseases; grant U54CA260491 (Dr. Pekosz, Dr. Karaba) from the National Cancer Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective observational study of SARS-CoV-2 vaccine response in solid organ transplant recipients was approved by the Johns Hopkins IRB (IRB00248540).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors150+150mg T+C150mg Tixagevimab and 150mg Cilgavimab300+300mg T+C300mg Tixagevimab and 300mg CilgavimabAnti-Nanti-nucleocapsidAUarbitrary unitsBAUbinding antibody unitsEIAEnzyme ImmunoassayFDAUS Food and Drug AdministrationIQRinterquartile rangeMMFmycophenolatemRNAmessenger RNAMSDMeso Scale Diagnostics (MSD)PrEPpre-exposure prophylaxisRBDReceptor Binding DomainSARS-CoV-2severe acute respiratory syndrome coronavirus 2SOTRsolid organ transplant recipientsT+CTixagevimab and CilgavimabULOQupper limit of quantificationVOCvariants of concern (VOC)